Diabetes Care
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Diabetes Care 30:181 2007
DOI: 10.2337/dc06-1745
© 2007 by the American Diabetes Association
This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bokhari, S.
Right arrow Articles by Meyer, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bokhari, S.
Right arrow Articles by Meyer, C.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Letters: Observations

Effects of Angiotensin II Type 1 Receptor Blockade on ß-Cell Function in Humans

Syed Bokhari, MD, Zarmen Israelian, MD, Jonelle Schmidt, RN, Eliot Brinton, MD and Christian Meyer, MD

From the Division of Endocrinology, Carl T. Hayden VA Medical Center, Phoenix, Arizona

Address correspondence to Dr. Christian Meyer, MD, Carl T. Hayden VA Medical Center, 650 East Indian School Rd., Phoenix, AZ 85012. E-mail: christian.meyer{at}med.a.gov.

Evidence indicates that activation of the angiotensin II type 1 receptor (AT1R) acutely decreases insulin secretion in animals and humans (1–3), mediated at least partially by reductions in islet blood flow and proinsulin biosynthesis (1,2). In contrast, AT1R blockade increased insulin secretion by 40–60% in Zucker diabetic fatty (ZDF) rats (4) and in obese db/db mice (5), thereby delaying the otherwise premature onset of diabetes in the latter animal model. If this were the case in humans, it would provide an explanation for the finding that AT1R antagonist treatment reduces the incidence of type 2 diabetes by ~25% in high-risk individuals in clinical trials despite no improvement in insulin sensitivity in most human studies using the euglycemic clamp technique (6).

We therefore studied the effects of 6 weeks of treatment with the AT1R antagonist valsartan (80 mg b.i.d.) on ß-cell function and insulin sensitivity in 16 subjects with impaired glucose tolerance (75% male; age 58 ± 2 years; BMI 33 ± 2 kg/m2), using a double-blind, placebo-controlled, randomized, cross-over design. We ensured that all subjects had a blood pressure <130/80 mmHg with or without antihypertensive medications (other than ACE inhibitors or AT1R antagonists) before the study, so as to minimize any potential influence of blood pressure lowering by AT1R antagonist treatment on metabolic outcomes. Three-hour hyperglycemic clamps (~10 mmol/l) with [3-3H]glucose infusion and indirect calorimetry, followed by intravenous arginine infusion (5 g over 30 s), were performed at the end of both treatment periods for the measurement of glucose-stimulated first- and second-phase insulin secretion, insulin secretory capacity, as well as different aspects of insulin sensitivity. The study was designed to detect 12.5% increases in first- and second-phase insulin secretion with 90% power.

Contrary to our hypothesis, AT1R blockade had no effect on either glucose-stimulated first- (188 ± 13 vs. 184 ± 15 pmol/l, P > 0.6) and second-phase insulin secretion (362 ± 35 vs. 337 ± 31, P > 0.2) or insulin secretory capacity (1,731 ± 128 vs. 1,714 ± 136 pmol/l, P > 0.8). Moreover, whole-body insulin sensitivity, suppression of endogenous glucose production, and stimulation of glucose disposal and glucose oxidation remained unchanged during the clamp (all P > 0.6); suppression of plasma free fatty acid and glucagon also remained unaltered (both P > 0.4).

The present study provides the novel information that, contrary to the studies in rodents (4,5), short-term AT1R blockade does not improve ß-cell function in humans who have impaired glucose tolerance, which may be due to species differences. Interestingly, in ZDF rats the improved ß-cell function by AT1R blockade was associated not only with increased islet proinsulin content but also with attenuated islet fibrosis and ß-cell apoptosis (4). If attenuated islet fibrosis and ß-cell apoptosis were important for improved insulin secretion by AT1R blockade in humans, it would probably be seen only with more prolonged treatment than that tested in the present study.

We conclude that short-term AT1R antagonist treatment improves neither ß-cell function nor insulin responsiveness in various insulin-sensitive tissues in humans. Whether more prolonged AT1R antagonist treatment can benefit human ß-cell function remains to be determined.

Acknowledgments

The present work was supported in part by an unrestricted investigator-initiated research grant from Novartis Pharmaceuticals and an American Diabetes Association Career Development Award to C.M.

Footnotes

E.B. is presently associated with the Department of Cardiovascular Genetics, University of Utah School of Medicine, Salt Lake City, Utah, and is a Speaker's Bureau Member for GlaxoSmithKline, Takeda, Pfizer, and Merck

References

  1. Carlsson PO, Berne C, Jansson L: Angiotensin II and the endocrine pancreas: effects on islet blood flow and insulin secretion in rats. Diabetologia 41:127–133, 1998[Medline]
  2. Lau T, Carlsson PO, Leung PS: Evidence for a local angiotensin-generating system and dose-dependent inhibition of glucose-stimulated insulin release by angiotensin II in isolated pancreatic islets. Diabetologia 47:240–248, 2004[Medline]
  3. Fliser D, Schaefer F, Schmid D, Veldhuis JD, Ritz E: Angiotensin II affects basal, pulsatile, and glucose-stimulated insulin secretion in humans. Hypertension 30:1156–1161, 1997[Abstract/Free Full Text]
  4. Tikellis C, Wookey PJ, Candido R, Andrikopoulos S, Thomas MC, Cooper ME: Improved islet morphology after blockade of the renin-angiotensin system in the ZDF rat. Diabetes 53:989–997, 2004[Abstract/Free Full Text]
  5. Chu KY, Lau T, Carlsson P-O, Leung PS: Angiotensin II type 1 receptor blockade improves ß-cell function and glucose tolerance in a mouse model of type 2 diabetes. Diabetes 55:367–374, 2006[Abstract/Free Full Text]
  6. Scheen AJ: Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 64:2537–2565, 2004[Medline]

Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Extract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bokhari, S.
Right arrow Articles by Meyer, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bokhari, S.
Right arrow Articles by Meyer, C.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum